Journal articleProc Natl Acad Sci U S A2022
XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer.
- Journal
- Proc Natl Acad Sci U S A
- Published
- 1 January 2022
- Citations
- 42
- Type
- Article
- License
- cc by-nc-nd
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Grants 10
- Augmenting Pancreatic Cancer Immunotherapy via TGFβ Pathway Inhibition F30CA236031↗
- Targeting MNK Pathways in Pancreatic Cancer I01BX002922↗
- Exploiting the Cross-talk between Neurotrophin Receptors and Mixed Lineage Kinases to Target Pancreatic Cancer. I01BX004903↗
- Ex vivo slice cultures of mouse pancreatic tumors to test novel regimens I21BX005693↗
- BLR&D Research Career Scientist Award Application IK6BX004855↗
- Targeting BET Bromodomain in Pancreatic Cancer R01CA186885↗
- Galpha13 and pancreatic cancer progression R01CA217907↗
- Use of BCL-xL Proteolysis targeting chimeras to treat pancreatic cancer R01CA242003↗
- Co-targeting BET Bromodomain Proteins and MNK Kinases in Pancreatic Cancer R01CA265997↗
- Rapid evaluation of immunotherapy regimens in ex vivo human pancreatic tumor slice cultures. R21CA255291↗